Wantai Biological Pharmacy Enterprise: The test systems of the immunofermental analysis for determination of antibodies to SARS-CoV-2

Main article: Antibodies to COVID-19 coronavirus

2020: Delivery plans to Russia

On July 14, 2020 it became known that test systems for determination of antibodies to SARS-CoV-2 from Wantai Biological Pharmacy Enterprise company will appear in Russia and EEU.

The number of the patients with COVID-19 coronavirus in the first decade of July, 2020 around the world reached 12 million people. In spite of the fact that the first peak of a disease is passed, the next disease outbreaks in the different countries of the world are registered, in the USA and the states of South America the daily gain breaks records. Therefore need for the most exact and operational diagnostics increases.

Shortly in Russia the countries of EEU there will be two new test systems of the immunofermental analysis for determination of antibodies to SARS-CoV-2 recognized by Erasmus's University in Rotterdam (Erasmus University Rotterdam).

The Kosmofarm company in April, 2020 signed the agreement on the license and distribution in the territory of Russia and the countries of EEU of products of the Chinese Wantai Biological Pharmacy Enterprise. And already in July, 2020, brings to the Russian market two test systems of the immunofermental analysis for determination of antibodies to SARS-CoV-2 from the producer from the People's Republic of China. On July 2, 2020 the Kosmofarm company received registration certificates on test systems for immunofermental determination of immunoglobulins of class M and total immunoglobulins of the class M and G to SARS-CoV-2 coronavirus antigen in serum and plasma of blood, production "Wantai Biological Pharmacy Enterprise Co., Ltd": N RZN 2020/11114 (IGM) and RZN 2020/11163 (IgM+IgG).

To the middle of June, 2020 the company delivered about 6.5 million serological tests for Covid-19 worldwide. Test systems have marking of the European Union and are delivered to EU countries according to the public and private contracts, and for July, 2020 have good scientific and clinical base. Sets of reagents are intended for determination of the immune status to Covid-19 and can be used for screening of the patients suspected on an infection by the SARS-CoV-2 virus as the instrument of laboratory diagnosis of a koronavirusny disease COVID-19. Test systems can work both at semi-automatic, and on automatic IFA-analyzers. Delivery of the first batch for Kosmofarm LLC (a plant louse of distribution in Russia and the countries of EEU) is expected in July, 2020.

Partnership with Kosmofarm LLC will allow to provide as much as possible clients in these countries with our test systems and to help to cope with distribution of Сovid-19 in the territory of EEU.

We lay great hopes on partnership with Wantai company, with more than 30 years' experience of equipment manufacturing for laboratory diagnosis of infectious diseases. IFA of a test system from Wantai head the European ratings of indicators of sets of instruments for diagnosis on antibodies to SARS-CoV-2 which include global manufacturers, and we are sure of the same appreciation from our clients and partners in the Russian Federation and other member states of EEU.